Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desflurane + propofol
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
A combination anesthetic approach using desflurane (an inhalational anesthetic) and propofol (an intravenous sedative-hypnotic agent). This combination provides synergistic effects for induction and maintenance of general anesthesia, offering more stable hemodynamics than propofol alone in certain procedures. Both agents act on the central nervous system through different but complementary mechanisms.
- Brand names
- DiprivanSuprane
- Other names
- 2,6-diisopropylphenolDesflurane, USP
02
Targets
GABRR (GABA-A receptor subunit rho)GLRA1 (Glycine receptor subunit Alpha-1)
Beyond the preview
Go deeper on desflurane + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desflurane + propofol.